Literature DB >> 1696598

Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level.

R I Connor1, L Shen, M W Fanger.   

Abstract

In this report we present evidence that not all human peripheral blood monocytes mediate antibody-dependent cellular cytotoxicity (ADCC), and that this function may be determined on an individual cell by both the type and level of expression of FcR, and by the state of cellular activation and/or differentiation. Although the diverse range of effector and regulatory functions performed by human monocytes suggests the possibility of distinct subsets, it is not clear whether observed functional heterogeneity reflects the presence of true monocyte subpopulations, or whether this diversity represents a continuum of maturational states present in the peripheral circulation. In an attempt to address this question, we investigated the ability of human monocytes to carry out ADCC at the single cell level, with emphasis on the role of the three FcR for IgG (Fc gamma RI, Fc gamma RII, and Fc gamma RIII) in mediating cytotoxicity. Using a modified plaque assay, 58.3% +/- 4.9 of freshly isolated monocytes mediated ADCC, as evidenced by the formation of lytic plaques in monolayers of ox erythrocyte (oxE) target cells. Significant increases in the number of plaque-forming cells were observed after positive selection by flow microfluorimetry for those monocytes expressing high levels of Fc gamma RI and Rc gamma RII, but not Fc gamma RIII. Bispecific antibodies composed of Fab fragments of anti-oxE antibody covalently coupled to Fab fragments of anti-Fc gamma R antibodies were used to independently evaluate the ability of Fc gamma RI, Fc gamma RII, and Fc gamma RIII to mediate single cell cytotoxicity. Significant increases in the number of plaque-forming cells were observed in the presence of anti-Fc gamma RI x anti-oxE and anti-Fc gamma RII x anti-oxE bispecific antibodies, confirming the efficiency of Fc gamma RI and Fc gamma RII as cytotoxic trigger molecules on human monocytes. Incubation of monocytes with purified rIFN-gamma and granulocyte macrophage-CSF, but not IL-2, IL-3, IL-4, IL-6, or TNF-alpha, also resulted in significant increases in the number of monocytes mediating cytotoxicity, suggesting that cytotoxic ability at the single cell level may be influenced by factors which effect monocyte activation and differentiation, respectively. Overall, these studies demonstrate that freshly isolated human monocytes are heterogeneous in their ability to mediate ADCC, and suggest that this functional diversity arises not from discrete subpopulations of cells, but from a continuum of maturational/activational states present within the peripheral circulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Alteration in human mononuclear leucocytes following space flight.

Authors:  R T Meehan; L S Neale; E T Kraus; C A Stuart; M L Smith; N M Cintron; C F Sams
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes.

Authors:  E X Deramoudt; C Gilard; N Lepine; J M Alonso; J L Romet-Lemonne
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

3.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 4.  Granulocyte-macrophage colony-stimulating factor and the immune system.

Authors:  P E Tarr
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

Review 5.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

6.  A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.

Authors:  Michael J Robertson; Christopher W Stamatkin; David Pelloso; Jill Weisenbach; Nagendra K Prasad; Ahmad R Safa
Journal:  J Immunother       Date:  2018-04       Impact factor: 4.456

7.  Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.

Authors:  P Ragnhammar; G Masucci; J E Frödin; A L Hjelm; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.

Authors:  Michael J Robertson; Justin Kline; Herbert Struemper; Kevin M Koch; John W Bauman; Olivia S Gardner; Sharon C Murray; Fiona Germaschewski; Jill Weisenbach; Zdenka Jonak; John F Toso
Journal:  J Immunother       Date:  2013 Jul-Aug       Impact factor: 4.456

9.  Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta.

Authors:  M Kruger; S Van Gool; X H Peng; L Coorevits; M Casteels-Van Daele; J L Ceuppens
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

10.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

Authors:  P Ragnhammar; I Magnusson; G Masucci; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.